scholarly journals Risk of second primary cancer in men with breast cancer

2007 ◽  
Vol 9 (1) ◽  
Author(s):  
Sacha Satram-Hoang ◽  
Argyrios Ziogas ◽  
Hoda Anton-Culver
Keyword(s):  
Breast Cancer ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer

scholarly journals Second primary cancer after female breast cancer: Familial risks and cause of death

2018 ◽  
Vol 8 (1) ◽  
pp. 400-407 ◽  
Author(s):  
Guoqiao Zheng ◽  
Akseli Hemminki ◽  
Asta Försti ◽  
Jan Sundquist ◽  
Kristina Sundquist ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cause Of Death ◽  
Female Breast Cancer ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Female Breast

scholarly journals Effect of breast cancer as the first or second primary cancer on the prognosis of women with thyroid cancer: a SEER database analysis

2020 ◽  
Vol 9 (11) ◽  
pp. 6955-6962
Author(s):  
Jianglong Huang ◽  
Yihui Huang ◽  
Ling Zhou ◽  
Sichao Chen ◽  
Danyang Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Thyroid Cancer ◽  
Second Primary ◽  
Primary Cancer ◽  
Seer Database ◽  
Second Primary Cancer ◽  
Database Analysis

Development of second primary cancers in breast cancer survivors.

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 257-257
Author(s):  
Hong Kyu Jung ◽  
Jihyoun Lee ◽  
Zisun Kim ◽  
Min Hyuk Lee ◽  
Ilkyun Lee
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Thyroid Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Breast Cancer Patients ◽  
Second Primary Cancers

257 Background: Breast cancer survivors have slightly increased risk of second primary cancers. Importance of screening for second cancers has been raised due to increased survival in those populations. Not only having genetic risk such as BRCA mutation, but also treatment-related risk presents. The most common second primary cancer is breast cancer. Colon cancer, uterine cancer, and ovarian cancer showed increased cumulative incidence. In this study, we assessed development second primary cancers in breast cancer survivors. Methods: Medical record of breast cancer patients was reviewed retrospectively in three tertiary medical institutions. Available data of ICD-9 record after breast cancer diagnosis was evaluated. Diagnosis of second primary breast cancer was excluded in evaluation. Results: Since Jan 1989 to Jan 2014, available medical records were reviewed in breast cancer patients(N = 5880) in three institutions(one urban and the other two rural institutions). Cumulative incidence of overall second primary cancers was 4.57%. Among 269 second primary cancers, thyroid cancer(44.2%) was most common second primary cancer, followed by gastric cancer(10.0%). Gastric cancers were more common in rural institution than urban area(14.2 % vs 5.5%), while incidence of thyroid cancer is elevated in urban institution(57.8% vs 31.9%). Among 9 patients who has been diagnosed endometrial cancer, 7 patients had history of selective estrogen receptor modulator(tamoxifen or toremifen) treatment. Development of lung cancer was not related to breast cancer radiation treatment(4 of 15 patients). Leukemia after breast cancer treatment was diagnosed in 5 patients (8.5% of second primary cancers), three of them were adult T cell leukemia and two of them were acute myeloid leukemia. Conclusions: Incidence of cancer in general population was reflected to development of second primary cancer in breast cancer survivors. Endocrine treatment was related increased incidence of endometrial cancer, respectively. Application of personalized cancer screening plan would be important in this patient group.

scholarly journals Risk factors and prediction of second primary cancer in primary female non-metastatic breast cancer survivors

Aging ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 19628-19640
Author(s):  
Xiwen Qian ◽  
Huixun Jia ◽  
Yue Zhang ◽  
Bingqing Ma ◽  
Guoyou Qin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Metastatic Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Metastatic Breast ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer

Abstract C87: Risk of second primary cancer (SPC) after breast cancer: A pooled analysis of Hispanic and non-Hispanic white women from New Mexico

2014 ◽  
Author(s):  
Avonne E. Connor ◽  
Richard N. Baumgartner ◽  
Stephanie D. Boone ◽  
Christina M. Pinkston ◽  
Kathy B. Baumgartner
Keyword(s):  
Breast Cancer ◽  
New Mexico ◽  
White Women ◽  
Pooled Analysis ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Hispanic White

scholarly journals Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers

2020 ◽  
pp. 916-925
Author(s):  
Kara N. Maxwell ◽  
Brandon M. Wenz ◽  
Abha Kulkarni ◽  
Bradley Wubbenhorst ◽  
Kurt D’Andrea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Susceptibility ◽  
Susceptibility Genes ◽  
Mutation Rates ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Data Set ◽  
Cancer Susceptibility Genes ◽  
Multiple Primary

PURPOSE Women with breast cancer have a 4%-16% lifetime risk of a second primary cancer. Whether mutations in genes other than BRCA1/2 are enriched in patients with breast and another primary cancer over those with a single breast cancer (S-BC) is unknown. PATIENTS AND METHODS We identified pathogenic germline mutations in 17 cancer susceptibility genes in patients with BRCA1/2-negative breast cancer in 2 different cohorts: cohort 1, high-risk breast cancer program (multiple primary breast cancer [MP-BC], n = 551; S-BC, n = 449) and cohort 2, familial breast cancer research study (MP-BC, n = 340; S-BC, n = 1,464). Mutation rates in these 2 cohorts were compared with a control data set (Exome Aggregation Consortium [ExAC]). RESULTS Overall, pathogenic mutation rates for autosomal, dominantly inherited genes were higher in patients with MP-BC versus S-BC in both cohorts (8.5% v 4.9% [ P = .02] and 7.1% v 4.2% [ P = .03]). There were differences in individual gene mutation rates between cohorts. In both cohorts, younger age at first breast cancer was associated with higher mutation rates; the age of non–breast cancers was unrelated to mutation rate. TP53 and MSH6 mutations were significantly enriched in patients with MP-BC but not S-BC, whereas ATM and PALB2 mutations were significantly enriched in both groups compared with ExAC. CONCLUSION Mutation rates are at least 7% in all patients with BRCA1/2 mutation–negative MP-BC, regardless of age at diagnosis of breast cancer, with mutation rates up to 25% in patients with a first breast cancer diagnosed at age < 30 years. Our results suggest that all patients with breast cancer with a second primary cancer, regardless of age of onset, should undergo multigene panel testing.

Sign in / Sign up

Export Citation Format

Share Document